new glp 1 drugs Retatrutide for weight loss: Study shows 30% body weight loss Study predicts 16 new obesity

Using some naive assumptions here (that the average weight loss required for the average obese persons BMI to be below 30 and thus not categorized as obese, assuming x% of obese people take the drug and all experience the average reduction in body weight), we can see a picture emerge that shows the potential to disrupt a trend thats been forming for the past 50 years

Success on the scale increases a hunger for more success, increasing motivation

GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis

SIRT1 and phosphorylated AMPK were normalized to the -actin and total AMPK of each sample, respectively

A full month

J., Schmidt, W